do not combine dpp-4 inhibitors with glp-1 receptor agonists guideline Comparison of and DPP-4 inhibitors for type 2

Adult neurogenesis is severely affected in PD, although the exact mechanisms and effects of these changes are not fully understood, there may be a dynamic interaction between them and PD-related pathology

All statistics and clinical interpretations are sourced from published Phase 2 and Phase 3 trial results as of October 2025

Therefore, there is a need to design studies that not only focus on the percentage but also investigate the body composition changes that accompany weight loss [46,47,48,49]

10.2147/IJN.S479670

Confusion about this drives many purchasing mistakes

Conflict of interest JR-F declares that he has received honoraria for lectures for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Novartis, Abbvie, Merck, and Bayer